4-821-725
[1]. Abhishek Juluri, et al. Minimally invasive transdermal delivery of iron-dextran. J Pharm Sci. 213 Mar;12(3):987-93.
[2]. Dae-Hyoung Lee, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 213 Jun;41(6):539-46.
[3]. Iain C Macdougall, et al. Use of intravenous iron supplementation in chronic kidney disease: an update. Iran J Kidney Dis. 213 Jan;7(1):9-22.
[4]. Jeffrey A Gilreath, et al. Total dose iron dextran infusion in cancer patients: is it SaFe2+?. J Natl Compr Canc Netw. 212 May;1(5):669-76.
[5]. Marco Musumeci, et al. The C57BL/6 genetic background confers cardioprotection in iron-overloaded mice. Blood Transfus. 213 Jan;11(1):88-93.
H317-H35
P261-P272-P28-P32+P352-P362+P364-P45-P51
GHS7,GHS8
沪ICP备1719645号
